These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8577053)

  • 1. [Disorders of sphingolipid activator proteins].
    Suzuki Y
    Nihon Rinsho; 1995 Dec; 53(12):3025-7. PubMed ID: 8577053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside.
    Hiraiwa M; Martin BM; Kishimoto Y; Conner GE; Tsuji S; O'Brien JS
    Arch Biochem Biophys; 1997 May; 341(1):17-24. PubMed ID: 9143348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lysosomal enzymes, sphingolipid activator proteins, and protective protein].
    Suzuki Y
    Nihon Rinsho; 1995 Dec; 53(12):2887-91. PubMed ID: 8577030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sphingolipid activator protein deficiency].
    Suzuki Y
    Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):471-4. PubMed ID: 11031998
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.
    Schmid B; Paton BC; Sandhoff K; Harzer K
    Hum Genet; 1992 Jul; 89(5):513-8. PubMed ID: 1634229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of splicing for prosaposin sorting.
    Madar-Shapiro L; Pasmanik-Chor M; Vaccaro AM; Dinur T; Dagan A; Gatt S; Horowitz M
    Biochem J; 1999 Feb; 337 ( Pt 3)(Pt 3):433-43. PubMed ID: 9895286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
    Schwarzmann G; Wendeler M; Sandhoff K
    Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate binding properties of the human liver hexosaminidase A activator protein.
    Hechtman P; Isaacs C; Smith-Jones L
    Can J Biochem Cell Biol; 1985 Aug; 63(8):830-8. PubMed ID: 2933135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity.
    Regis S; Filocamo M; Corsolini F; Caroli F; Keulemans JL; van Diggelen OP; Gatti R
    Eur J Hum Genet; 1999; 7(2):125-30. PubMed ID: 10196694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse.
    Matsuda J; Kido M; Tadano-Aritomi K; Ishizuka I; Tominaga K; Toida K; Takeda E; Suzuki K; Kuroda Y
    Hum Mol Genet; 2004 Nov; 13(21):2709-23. PubMed ID: 15345707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor.
    Burkhardt JK; Hüttler S; Klein A; Möbius W; Habermann A; Griffiths G; Sandhoff K
    Eur J Cell Biol; 1997 May; 73(1):10-8. PubMed ID: 9174667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sphingolipid activator protein deficiency].
    Inui K
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):756-9. PubMed ID: 3270890
    [No Abstract]   [Full Text] [Related]  

  • 13. Degradation of membrane-bound ganglioside GM1. Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP.
    Wilkening G; Linke T; Uhlhorn-Dierks G; Sandhoff K
    J Biol Chem; 2000 Nov; 275(46):35814-9. PubMed ID: 10942779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 15. Activator proteins and topology of lysosomal sphingolipid catabolism.
    Fürst W; Sandhoff K
    Biochim Biophys Acta; 1992 Jun; 1126(1):1-16. PubMed ID: 1606169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing of sphingolipid activator proteins and the topology of lysosomal digestion.
    Sandhoff K; Kolter T
    Acta Biochim Pol; 1998; 45(2):373-84. PubMed ID: 9821868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB.
    Hechtman P; Gordon BA; Ng Ying Kin NM
    Pediatr Res; 1982 Mar; 16(3):217-22. PubMed ID: 6801612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides.
    Lamontagne S; Potier M
    J Biol Chem; 1994 Aug; 269(32):20528-32. PubMed ID: 8051151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of saposins (sphingolipid activator proteins) in tissues of lysosomal storage disease patients.
    Tayama M; O'Brien JS; Kishimoto Y
    J Mol Neurosci; 1992; 3(4):171-5. PubMed ID: 1389998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural organization and expression of the gene for the mouse GM2 activator protein.
    Bertoni C; Appolloni MG; Stirling JL; Li SC; Li YT; Orlacchio A; Beccari T
    Mamm Genome; 1997 Feb; 8(2):90-3. PubMed ID: 9060405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.